Development of VISTA in tumor immunotherapy / 中国药科大学学报

@#V-domain immunoglobulin suppressor of T-cell activation (VISTA) is a member of the B7 family that maintains homeostasis in T cells and myeloid cells.Blocking VISTA inhibits tumor development in in vitro and in vivo trials, and is an important target for tumor immunotherapy.This review focuses on its structural features, expression and biological functions in tumor microenvironment, summarizes the current stage of small molecule inhibitors and antibodies targeting VISTA, and discusses the research approaches.It aims to provide a rationale for subsequent study on VISTA and the development of related immune checkpoint antitumor drugs.

Correlation Between STK11 Gene Mutation and Immunotherapy of Non-small Cell Lung Cancer / 肿瘤防治研究

Lung cancer is one of the most common malignant tumors. Globally, the incidence and mortality of lung cancer are very high and on the rise. In recent years, immune checkpoint inhibitors (ICIs) have a significant survival advantage in treating advanced NSCLC. However, for NSCLC patients with positive driver genes, ICIs are not effective. But some tumor suppressor genes have varying degrees of impact on immunotherapy through mutations or deletions. Among them, serine/threonine kinase 11 (STK11) gene mutations are closely related to PD-1/PD-L1 ICIs. Studies have found that STK11 mutations are related to reduced immune cell infiltration, low PD-L1 expression and poor response to PD-L1 inhibition. This article reviews the research progress of the correlation between STK11 gene mutation and immunotherapy on NSCLC.

Research progress of thyroid dysfunctions during treatment with immune-checkpoint inhibitors / 中国临床药理学与治疗学

Thyroid dysfunction (TD) is one of the commonest endocrine immunotherapy-related adverse events (IRAEs) during cancer patients' treatment with immune checkpoint inhibitors (ICIs). In the hope that cooperation between departments will be enhanced to alleviate the side effect of immunotherapy which thyroid dysfunctions can cause, this review is contributed to make more endocrinologists and oncologists acknowledge and master clinical characteristics, diagnostic methods and therapeutic strategies of thyroid IRAEs, by the introduction of its pathogenesis, epidemiological features, diagnosis, treatment and prognosis.